Inscripta News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Inscripta. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Inscripta Today - Breaking & Trending Today

INSCRIPTA® ACQUIRES INFINOME BIOSCIENCES AND SESTINA BIO TO ADVANCE SUSTAINABLE BIOMANUFACTURING

/PRNewswire/ Inscripta, a global leader in genome engineering technology, announced today the acquisition of two pioneers of synthetic biology – Infinome. ....

United States , Richard Fox , Infinome Biosciences , Prnewswire Inscripta , Andrew Horwitz , Michaelb Gonzales , Ted Tarasow , Inscripta Inc , Sestina Bio , Sri Kosaraju , Vice President ,

SESTINA BIO USES INSCRIPTA'S ONYX® PLATFORM TO DEVELOP MICROBIAL STRAIN READY FOR SCALE-UP IN LESS THAN 12 MONTHS

/PRNewswire/ Inscripta, Inc., a global leader in automated, CRISPR-based gene editing technology, and Sestina Bio, LLC, a synbio pioneer leveraging. ....

United States , San Diego , Andrew Horwitz , Michaelb Gonzales , Ted Tarasow , Sestina Bio , Inscripta Inc , Prnewswire Inscripta Inc , Sri Kosaraju ,

Inscripta closes $150M VC round, scores first commercial buyer of CRISPR gene editing platform


Apr 5, 2021 3:30pm
Inscripta’s latest funding round will support the development and distribution of its Onyx benchtop platform, which uses CRISPR gene editing technology for fully automated genomic engineering. (AstraZeneca)
Inscripta just got another step closer to achieving its mission of bringing CRISPR gene editing technology to the scientific masses.
The genomic engineering company, a member of Fierce Medtech’s 2019 Fierce 15, recently closed a series E funding round totaling $150 million. The investment was led by Fidelity Management and Research Company and funds and accounts managed by T. Rowe Price Associates.
Upon the close of a $125 million series D round in December 2019, Inscripta calculated its total amount of funds raised since its 2015 founding at $259.5 million. With the latest influx of funds and an extension of the series D in November 2020, that total now clocks in at well over $450 million. ....

University Of Liverpool Genemill , Research Company , T Rowe Price Associates , Fierce Medtech , Fidelity Management , Sestina Bio , Gene Editing , Genetic Engineering , Synthetic Biology , ஆராய்ச்சி நிறுவனம் , டி ரோ ப்ரைஸ் கூட்டாளிகள் , கடுமையான மெதிதேச் , நம்பகத்தன்மை மேலாண்மை , செஸ்டினா உயிர் , கீந் திருத்துதல் , ஜெநெடிக் பொறியியல் , செயற்கை உயிரியல் ,